Liver Function in 31 Evaluable Patients According to HGV Status and Treatment Modalities After Completion of Drug Therapy
. | HGV-RNA . | |||
---|---|---|---|---|
Positive . | Negative . | |||
BMT (n = 6) . | Chemotherapy (n = 4) . | BMT (n = 10) . | Chemotherapy (n = 11) . | |
Maximum ALT, IU/L (mean ± SD) | 88.0 ± 19.63-150,3-151 | 16.3 ± 0.4 | 37.2 ± 4.23-152 | 18.4 ± 5.0 |
Abnormal/total | 6/6 | 0/4 | 4/10 | 0/11 |
% Patients with abnormal levels | 100 | 0 | 40 | 0 |
Mean ALT (mean ± SD) | 44.9 ± 15.6 | 10.7 ± 0.8 | 20.9 ± 2.33-153 | 11.1 ± 2.9 |
. | HGV-RNA . | |||
---|---|---|---|---|
Positive . | Negative . | |||
BMT (n = 6) . | Chemotherapy (n = 4) . | BMT (n = 10) . | Chemotherapy (n = 11) . | |
Maximum ALT, IU/L (mean ± SD) | 88.0 ± 19.63-150,3-151 | 16.3 ± 0.4 | 37.2 ± 4.23-152 | 18.4 ± 5.0 |
Abnormal/total | 6/6 | 0/4 | 4/10 | 0/11 |
% Patients with abnormal levels | 100 | 0 | 40 | 0 |
Mean ALT (mean ± SD) | 44.9 ± 15.6 | 10.7 ± 0.8 | 20.9 ± 2.33-153 | 11.1 ± 2.9 |
All of the patients in the table were negative for other hepatopathic factors, including HCV-RNA, HBs antigen, autoimmune antibodies, and drug use. The values of mean ALT represent the average of the mean ALT values of each patient measured during each month of the hospital course.
Abbreviation: ALT, alanine aminotransferase, normal value <40 IU/L.
P = .0064 HGV-infected versus uninfected.
P = .0189 BMT versus chemotherapy.
P = .0003 BMT versus chemotherapy.
P = .0005 BMT versus chemotherapy.